Reading CUE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CUE free→Reading CUE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CUE free→QuarterlyIQ Insights · CUE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers At the Special Meeting of Stockholders of Cue Biopharma, Inc. (the “Company”) held on June 1, 2026 (the “Special Meeting”), the Company’s stockholders approved the Cue Biopharma, Inc. 2026 Stock Incentive Plan (the “2026 Plan”), which had previously been adopted by the Board, subject to stockholder approval. The description of the 2026 Plan containe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serv…
of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, except as expressly set forth by specific referen…
Other Events. On April 30, 2026, the Company issued a press release announcing, among other things, entry into the License Agreement. On April 30, 2026, the Company issued a press release announcing the Offering. The full text of each press release is attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking state…
Entry into a Material Definitive Agreement. Ascendant Health Sciences Ltd. License Transaction License Agreement On April 30, 2026, Cue Biopharma, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Ascendant Health Sciences Ltd., a Cayman Limited Company (the “Licensor”). Pursuant to the License Agreement and subject to certain rights retained by the Licensor, the Licensor granted the Company: (1) the exclusive and sublicensable rights to develop, manufacture…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Inducement Stock Incentive Plan On April 27, 2026, the Board adopted the Company’s 2026 Inducement Stock Incentive Plan (the “Inducement Plan”), pursuant to which the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stock-based awards, and performance awards with re…
Based in part upon the representations of the Licensor in the Purchase Agreement, the offering and sale of the Licensor Securities will be exempt from registration under Rule 903 of Regulation S promulgated under the Securities Act. The Licensor Securities have not been registered under the Securities Act or any state securities laws, and the Licensor Securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration re…
Material Modification to Rights of Security Holders. To the extent required by
Other Events On April 1, 2026, Cue Biopharma, Inc. (the “Company”) received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved selection of its first compound for lead optimization under the Collaboration and License Agreement entered into with Boehringer Ingelheim on April 10, 2025 for the research, development and commercialization of differentiated B cell depletion molecules, including the Company’s CUE-501 product candidate. This preclinical milestone event triggers a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. President and Chief Executive Officer Appointment and Resignation On March 26, 2026, the Board of Directors (the “Board”) of Cue Biopharma, Inc. (the “Company”) appointed Lucinda Warren, the Chief Financial and Business Officer of the Company, as Interim President and Chief Executive Officer, effective as of March 27, 2026 (the “Effective Date”). M…
Results of Operations and Financial Condition. On March 16, 2026, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 9, 2026, the Board of Directors of Cue Biopharma, Inc. (the “Company”) appointed Lucinda Warren, the Chief Business Officer of the Company, as Chief Financial and Business Officer of the Company, effective February 9, 2026. Upon commencement of her appointment, Ms. Warren assumed the duties of the Company’s principal financial officer a…
Entry into a Material Definitive Agreement. On December 19, 2025, Cue Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of (i) 12,500,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and accompanying common sto…
Other Events. The full text of the press release announcing the pricing of the underwritten public offering on December 19, 2025 is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Cash Runway Based upon the Company’s current plans and forecasted expenses, the Company estimates that the net proceeds from the underwritten offering, together with the Company’s existing cash, cash equivalents and marketable securities, including the $5.0 million in upfront payments the Co…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 17, 2025, Cue Biopharma, Inc. (the “Company”) and Matteo Levisetti, Chief Medical Officer, agreed that Dr. Levisetti’s employment with the Company will terminate effective November 28, 2025 (the “Separation Date”). In connection with his departure, Dr. Levisetti is entitled, subject to his execution and nonrevocation of a separation and…
Results of Operations and Financial Condition. On November 12, 2025, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange A…
Entry into a Material Definitive Agreement. On November 6, 2025, ImmunoScape Pte. Ltd. (“IMSCP”) exercised its option (the “Option”) to obtain licenses to research, develop and commercialize molecules from Cue Biopharma, Inc.’s (the “Company”) CUE-100 Series, including CUE-101 and CUE-102, subject to certain exclusions (the licensed series of molecules, the “Licensed Program”), for all oncology indications pursuant to a Collaboration and License Agreement, effective November 6, 2025, between…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Executive Officer Appointment and Resignation On September 26, 2025, the Board of Directors (the “Board”) of Cue Biopharma, Inc. (the “Company”) appointed Usman Azam as President and Chief Executive Officer and as a member of the Board, in each case effective as of September 29, 2025 (the “Effective Date”). Dr. Azam will succeed Daniel R. Pas…
Results of Operations and Financial Condition. On August 12, 2025, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…
Entry into a Material Definitive Agreement. On June 30, 2025, Cue Biopharma, Inc. (the “Company”) and MIL 40G, LLC (“Licensor”) entered into the Second Amendment to License Agreement (the “Second Amendment”) to that certain License Agreement, dated March 28, 2022 and amended by the First Amendment to License Agreement, dated May 3, 2022 (as so amended, the “License”). Pursuant to the Second Amendment, effective June 30, 2025, the monthly rental rate decreased from $235,883.98 to $147,545.69,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Director On June 4, 2025, Jill Broadfoot was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”), the Audit Committee of the Board, and the Corporate Governance and Nominating Committee of the Board, following the recommendation of the Corporate Governance and Nominating Committee of the Board. Ms. B…
Results of Operations and Financial Condition. On May 12, 2025, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…
Other Events. The full text of the press release announcing the pricing of the underwritten public offering on April 14, 2025 is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Cash Runway Based upon the Company’s current plans and forecasted expenses, the Company estimates that the net proceeds from the underwritten offering, together with the Company’s existing cash and cash equivalents, including an upfront payment of $12.0 million the Company will receive pursuant…
Entry into a Material Definitive Agreement. On April 14, 2025, Cue Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc., as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of (i) 13,530,780 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and accompanying common stock warrants…
Results of Operations and Financial Condition. On April 14, 2025, the Company disclosed in a preliminary prospectus supplement relating to the offering that, as of March 31, 2025, the Company estimates that it had $13.1 million in cash and cash equivalents. The estimated cash and cash equivalents amount is preliminary and unaudited, represents management’s estimate as of April 14, 2025, is subject to completion of the Company’s financial closing procedures for the three months ended March 31,…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.